Ascendis Health (JSE:ASC) 5-Year EBITDA Growth Rate: 0.00% (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JSE:ASC Ascendis Health Ltd JSE:ASC
11 GF Score
Price R0.92
View Full Analysis

What is Ascendis Health 5-Year EBITDA Growth Rate?

Ascendis Health JSE:ASC 11 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2023. GuruFocus rates JSE:ASC with a GF Score™ of 11/100.

Ascendis Health's EBITDA per Share for the six months ended in Jun. 2023 was R-0.19.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Ascendis Health  (JSE:ASC) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Ascendis Health 5-Year EBITDA Growth Rate Related Terms

JSE:ASC vs PHBI, GCAN, SGBI: 5-Year EBITDA Growth Rate Comparison

For the Medical Distribution subindustry, Ascendis Health's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascendis Health 5-Year EBITDA Growth Rate vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Ascendis Health's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Ascendis Health's 5-Year EBITDA Growth Rate falls into.


JSE:ASC
11GF Score
Ascendis Health Ltd JSE:ASC
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Health 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Ascendis Health (JSE:ASC) has a 5-Year EBITDA Growth Rate of 0.00% as of Jun. 2023. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Ascendis Health and its competitors.
Is Ascendis Health's 5-Year EBITDA Growth Rate too high?
Ascendis Health's current 5-Year EBITDA Growth Rate is 0.00%. Overall, Ascendis Health has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Health's 5-Year EBITDA Growth Rate compare to PHBI and GCAN?
Ascendis Health's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Distribution company?
A good 5-Year EBITDA Growth Rate depends on the Medical Distribution industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Ascendis Health and its competitors. Ascendis Health's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Health stock overvalued right now?
Ascendis Health (JSE:ASC) has a current 5-Year EBITDA Growth Rate of 0.00%. The current 5-Year EBITDA Growth Rate is 0.00%. Ascendis Health's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ascendis Health (JSE:ASC), the current 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Health Business Description

Address 1 Carey Street, Wynberg, Sandton, GT, ZAF, 2090
Ascendis Health Ltd is a health and wellness investment holding Company that holds investments in a number of companies that market and distribute a portfolio of brands, products, and medical devices. The company operates in two segments: i) Consumer Health (wellness, health supplements, speciality ingredients and compounded medicines) and ii) Medical Devices (distributor of medical devices, in vitro diagnostic products and orthopaedic equipment). The company generates the majority of its revenue from the Medical Devices segment.
11GF Score

Get the complete analysis for JSE:ASC

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R0.92
Price